Podcasts about CRISPR

Therapeutics, vaccines, Regeneron, will therapeutics replace vaccines?, the biotechnology industry, genetic engineering, Stanford, University of California at San Francisco (UCSF), the roll of the Bay area in biotech, advances in gene editing during the 1990s, mRNA and its links to therapeutics, Jesse Gelsinger, Bush II and bans on research, lipid nanoparticles (LNPs), the advent of synthetic biology, cell therapy, stem cells, embryonic stem cell controversy, CRISPR, CRISPR CaS9, Jennifer Dounda, Emmanuelle Cherpentier, Feng Zhang, Broad Institute, UC Berkeley, Intellia Therapeutics, CRISPR Therapeutics, Operation Warp Speed, Editas Medicine, Innovative Genomics Institute (IGI), Covid vaccines, why the Covid vaccines are more like a therapeutic, AI biotech, AlphaFold2, tech money piles into biotech post pandemic, Arc Institute, Vitalik Buterin, Big Pharma and its lack of involvement in therapeutics, Big Tech's entry into defense and healthcare, Peter Thiel, Thiel as the catalyst for modern therapeutic research, life-extension, Thiel's extensive investment in therapeutics and biotech, Jason Camm, Jim Mellon, Brexit, Thiel's lack of investment in CRISPRResourcesTrump on "miracle drugs":https://www.yahoo.com/news/article/trump-coronavirus-twitter-video-234914108.html?guccounter=1On the links between therapeutics and the Covid vaccineshttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02444-3/fulltexthttps://pmc.ncbi.nlm.nih.gov/articles/PMC12179814/AI Biotechhttps://whatisbiotechnology.org/index.php/science/summary/aiBig Tech and AI biotechhttps://www.forbes.com/sites/richardnieva/2024/03/13/why-nvidia-google-and-microsoft-are-betting-billions-on-biotechs-ai-future/How funding for biotech has unfolded since the 2010shttps://www.fiercebiotech.com/biotech/how-healthy-exchange-ideas-rfk-jr-kicked-fdas-gene-therapy-pushThiel's Links to Biotechhttps://www.technologyreview.com/2015/03/16/168909/a-contrarian-in-biotech/https://sociallifemagazine.com/celebrities/bezos-thiel-longevity-investments/https://www.inc.com/jeff-bercovici/emerald-therapeutics-peter-thiel.htmlhttps://www.fiercebiotech.com/biotech/thiel-s-breakout-labs-fuels-four-new-life-science-companieshttps://alloytx.com/42-million-series-d-financing/https://www.wholesaleinvestor.com/epiaxis-therapeutics-peter-thiel-backed-peptilogics-enter-strategic-partnership/https://www.businessinsider.com/peter-thiel-funded-de-extinction-animal-resurrection-woolly-mammoth-2017-6https://www.sfgate.com/tech/article/synthego-after-raising-forced-bankrupcty-20331773.phpJason Camm's biohttps://www.berentx.com/companyMusic by: Keith Allen Dennishttps://keithallendennis.bandcamp.com/ Hosted on Acast. See acast.com/privacy for more information.

Wellness trends move fast, yet volume two of The Next Frontier Files proves some predictions age well. Revisiting year two of the show, host Jenn Trepeck tracks the guests who forecasted metabolic health, gut health, and body positivity long before they became mainstream conversations, and shows how precision medicine and permission became the defining threads of an entire year.Jenn Trepeck brings listeners of Salad with a Side of Fries a look back at the guest predictions that shaped the year two, August 2020 - August 2021, grading them against what really happened since.What You Will Learn in This Episode:✅ How telehealth and virtual training went from pandemic workaround to a permanent part of everyday healthcare✅ Why metabolic health and gut health became two of the most repeated topics in wellness over the following years✅ What guests predicted about wearable technology, gene editing, and the future of human biology✅ How body positivity and permission-based wellness reshaped the conversation around health and self-imageThe Salad With a Side of Fries podcast, hosted by Jenn Trepeck, explores real-life wellness and weight-loss topics, debunking myths, misinformation, and flawed science surrounding nutrition and the food industry. Let's dive into real-life wellness and weight loss, including drinking, eating out, and skipping the grocery store.TIMESTAMPS:00:00 Year two overview explains how telehealth shifted from workaround to permanent wellness trends infrastructure04:42 Chad Levy discusses virtual training, and Amy Marshall shares her perspective on Telehealth and Zoom technology06:55 Chris Burres introduces longevity as a frontier, and Natasa Billeci mentions AI and propels the precision medicine conversation08:49 Toxin exposure and cellular absorption enter the conversation through Tim James' product launch12:01 Corey Phelps highlights her views on meditation and breathwork12:58 Dr. Casey Means discusses metabolic health tools and using technology to return to basics15:53 Gut health gets its first mention by Mike Millner, predicting it is only 2% understood16:53 Dr. Anthony Balduzzi predicts gene therapy, CRISPR, and implantable technology merging with human biology18:25 Catharine Arnston embraces preventative medicine19:13 Sarah Nilsen expounds about CBD and cannabinoid research20:12 Jay Shifman comments on BMI and asks why is it still being used21:17 Sarah Malouf and Farah M. Green raise body positivity and the pressure to redefine beauty standards23:20 Jenn closes by tying the year's predictions together under precision and permissionKEY TAKEAWAYS:

Have you heard about the radioactive wolves in Chernobyl? Or the latest gene-editing tech that's curing rare diseases? Or that male birth control might be on the horizon? No?!Well, get ready, because while we've been busy living our lives, genomics has been moving – fast! Things that once read like science fiction are moving on over to the non-fiction section.This season on Nice Genes!, join Dr. Kaylee Byers as she engages in some big genomics breakthroughs – from personalized cancer treatments, to how our bodies react in space, to how animals adapt to the most extreme environments, and whether we can actually change how we age.It's a whole new gene-eration (if you will) of discoveries that you won't want to miss!New episodes every two weeks, starting September 8th. Make sure you follow Nice Genes! so you don't miss an episode!

BEST OF: After our “AILIEN The Final Card” show, it became apparent that the push to grant mass “amnesty” to every person and agency involved in black budget programs was a dangerous narrative gaining more traction by the day, and now compounded by an executive order from the White House titled “Launching the Genesis Mission.” This program seeks to support, along with the AI regulation moratorium of the BBB, the narrative that “America is in a race for global technology dominance in the development of artificial intelligence (AI).” The first section states: “the challenges we face require a historic national effort, comparable in urgency and ambition to the Manhattan Project that was instrumental to our victory in World War II.” But what suddenly changed? Have other countries cracked the AI egg entirely or has, as the UFO community suggests, they reverse engineered alien tech fully? Even so, a dangerous nationwide Manhattan Project should be a secret, not a public initiative. One part of the EO says the goal is to develop "AI-enabled predictive models, simulation models, and design optimization tools,” things that have been sold to the public over and over again, from climate change to pandemic models, but which have all been wrong. But if AI says something is true based on a model, it must be correct. However, if AI is merely saying what is most likely based on current actions, like a tarot reading, then if all current policies are designed for war then isn't that what we will get? Isn't that what Alex Karp of Palantir said would happen? And isn't “Genesis” also “skynet”?For those left waiting for something “big” to happen it will be disappointing to learn that it already has. Engineered smart/micro-dust is currently turning the world into a giant sensor, while Sam Altman of the Stargate Project, OpenAI, and the Orb, is now funding CRISPR-based embryo gene editing as the alterer-of-man.And to keep us entertained during this slow-burn apocalyptic invasion, we have KION, an AI-created K-pop star who's clearly created with all he best black goo moments from Taylor Swift, Lady Gaga, Billie Eilish, and the like. It all makes sense if the gift of “UFO technology” may in fact be a series of blueprints to build the alien mind on earth; the name KION, from various languages, translates to ancient-foundation-leader-possessed. In other words, Lovecraft's Old Ones once more. But IT is being sold as a sexy black goo princess. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, subscribe below. 

The Counter Momentum of Spin, with Dr. Franco Musio – Dr. Li-Meng Yan examines how Chinese Communist Party influence shapes medical research, scientific collaboration, and US institutions. The discussion explores SARS-CoV-2 origins, cognitive warfare, Chinese students, Big Data manipulation, and the controversial CRISPR gene-editing case involving researcher He Jiankui while questioning ethics and national security...

Guest: Dr. Abdullah Khan is an Associate Professor of Tissue Engineering at the University of Oxford and a Group Leader at the MRC Weatherall Institute of Molecular Medicine. He discusses how his lab engineers complex human tissue models to study the cellular interactions that drive development, aging, and disease. He also explores how multi-organoid systems can model interactions between tissues such as the bone marrow and heart, and how these platforms could advance disease modeling, drug discovery, and preclinical research. Featured Products and Resources: Get a free wallchart on the derivation and applications of hPSCs. Subscribe to ESC & iPSC News to receive all of the latest research, news, jobs, and events in ESC & iPSC research. The Stem Cell Science Round Up Rescuing hPSC Differentiation – A chemical chromatin restoration approach reverses differentiation defects in human pluripotent stem cells, restoring their ability to generate diverse cell types and brain organoids. A Tumor Organoid Atlas – Patient-derived tumor organoids reveal cancer-specific gene dependencies and therapeutic vulnerabilities, providing a resource for advancing precision oncology. Mapping New Cancer Vulnerabilities – CRISPR screening of organoids and spheroids expands the Cancer Dependency Map, revealing cancer vulnerabilities and molecular subtypes missed by traditional cell lines. Building Better Cancer Models – A large collection of next-generation cancer models captures much of the genetic and epigenetic diversity of patient tumors, creating a resource for studying cancer biology and treatment response. Modeling Heart Valve Disease – Human iPSC-derived valve assembloid models heart valve development and reveals how mechanical forces and fluid flow shape valve formation and disease. Heart Valves in the Lab – Stem cell-derived 3D heart valve tissues recapitulate key features of valve maturation and provide a human platform for studying inflammation and calcific valve disease. Photo Reference: Courtesy of Dr. Abdullah Khan. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

On In The Market with Janet Parshall this week, Biochemist Dr. Fazale Rana discussed the pros and concerns of the new gene editing technology CRISPR. A former Muslim shared her journey to Christ and why we need to pray for Iranian believers who are facing increased persecution. Olivier Melnick from Shalom in Messiah ministries was back to address the ongoing attacks on Jews across the world and why popular accusations of colonization, occupation, apartheid and genocide by the Jews have no basis in history or truth. Dr. Sam Storms joined us for an important conversation about the exclusivity of the gospel and why Jesus is, was, and ever shall be the ONLY ways of salvation. He took us deep into John 14:6 & Romans 1:18-25 and explained why all of God’s word is focused on one goal: Salvation. The attack on efforts to lead people away from same-sex struggles is spreading, so Wayne Blakely shared with us a new documentary addressing this very serious issue and the ongoing attacks on religious freedom. It is time to put some of the biggest headlines of the week under the unflinching magnifying glass of God’s word.Become a Parshall Partner: http://moodyradio.org/donateto/inthemarket/partnersSee omnystudio.com/listener for privacy information.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. George Goshua, Gerd Blobel, and Paul Kaminski on their latest articles published in Blood. Dr. Goshua elaborates on the background and then insights from "Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis". This analysis provides valuable guidance for clinicians, patients, and health systems as they consider treatment choices. However, as concluded in the accompanying Blood Commentary, the true measure of success is not which therapy “wins” the economic argument, but whether each patient receives the therapy best suited to their clinical needs and values. Then, Drs. Gerd Blobel and Paul Kaminski share "Dissecting polycomb complexes for enhanced fetal hemoglobin production", which utilizes a comprehensive CRISPR-based screen to interrogate the components of these repressive complexes and identified a single protein domain in EZH2, a subunit of PRC2, as a potential therapeutic target. They demonstrate that inhibition of the domain encoded by exon 14 of EZH2 selectively derepresses fetal hemoglobin expression, raising the possibility of developing drugs that specifically target this domain to treat hemoglobinopathies.

AI can now read DNA like language, generate working biological sequences, and help scientists identify disease-related mutations. Radical Numerics CEO Eric Nguyen explains how genome language models work, why his earlier model Evo helped scientists design CRISPR systems and bacteriophage genomes, and how the company's newer model, Omnii, combines DNA with RNA, proteins, and other biological signals. The conversation explores personalized medicine, gene therapy, AI-designed biological threats, “deepfake viruses,” and whether the same technology that creates new biology can also defend against it.Learn more about Radical Numerics: https://www.radicalnumerics.ai/

At least 111 people are killed as a 7.4 magnitude earthquake hits Colombia, Netanyahu rejects a Trump-backed Gaza peace plan, Trump changes the U.S. child vaccine schedule, alleged Irish crime boss Kinahan is charged after extradition, seven people are killed as the Houthis strike a Yemen port and a Saudi refinery, a U.K. charity is investigated over alleged Hamas financing links, UEFA, CONCACAF and the Asian Football Confederation accuse Gianni Infantino of a "fundamental breach of trust," Typhoon Dolphin slams China as 1 million people are evacuated, the U.S. Department of Health and Human Services propose new scrutiny of food additives and ingredients, CRISPR gene editing produces the world's first hypoallergenic dogs. Sources: Verity.News

Christopher Mason, a geneticist and NASA investigator and author of The Next 500 Years: Engineering Life to Reach New Worlds, outlines a 500-year plan to enable human survival beyond Earth. Central to his vision is the deontogenic ethical framework, which asserts that humanity has a "genetic duty" to serve as guardians of life across the universe. To facilitate interstellar travel on generation ships, Mason proposes using advanced tools like CRISPR to edit human genomes and epigenomes to survive extreme environments. This includes adapting biological lessons from tardigrades for radiation resistance and bears for hibernation during long transit. He envisions "chloro-humans" capable of photosynthesis and humans who can synthesize their own essential vitamins. Beyond biological tweaks, Mason discusses ectogenesis (artificial uteruses) to manage human development during multi-generational journeys. While radical, Mason argues these modifications ensure "planetary liberty," allowing humans to inhabit worlds like Mars or Titan safely. (1)

This hour, Dr. Fazale Rana, from Reasons to Believe, will discuss gene-editing technologies such as CRISPR and how these advances are transforming medicine, giving scientists the ability to correct genetic disorders like cystic fibrosis and sickle cell anemia. But are they playing God? Then, you hear about an exciting on-line event being put together by Iran Alive ministries that take you beyond the headlines to give you keen insight into what it is like to live under a theocracy. Don’t miss a minute of this conversation.Become a Parshall Partner: http://moodyradio.org/donateto/inthemarket/partnersSee omnystudio.com/listener for privacy information.

If you love dogs but can't own one because of allergies, scientists may have a solution. In a new study, published in The CRISPR Journal, researchers used CRISPR gene editing to remove the gene responsible for producing the major protein called Can f 1 that triggers dog allergies in many people. Using CRISPR-Cas9, the scientists edited skin cells taken from the beagles. CRISPR acts a bit like molecular scissors, cutting DNA at a precise location. In this case, they introduced a tiny one-letter insertion into the Can f 1 gene that disrupted its instructions, preventing the protein from being made. Those edited cells were then used in somatic cell nuclear transfer, the same cloning technique used to create Dolly the sheep. The DNA from an edited cell was placed into a donor egg, creating an embryo carrying the genetic change. The team produced 25 embryos and implanted them into a surrogate beagle. Two embryos developed successfully and became puppies called Bailey and Alfie. The researchers then sequenced the puppies' DNA to confirm that the intended genetic change was present and checked if any other parts of the genome were accidentally edited. Next the scientists collected saliva, hair and dander from the edited beagles. They also collected samples from a normal beagle, a standard poodle and a goldendoodle. Using a laboratory technique called a Western blot, which detects specific proteins, they searched for Can f 1. The results showed the normal beagle, poodle and goldendoodle all produced the allergen but the gene-edited dogs didn't. This also reinforced something many allergy specialists have said for years: poodles and doodles still produce the major dog allergen despite often being described as hypoallergenic. Finally the experiment involved testing these new Beagles on humans with known dog allergies using a classic skin prick test. Tiny drops containing extracts from different dogs were placed on the volunteer's arm before gently pricking the skin. If the immune system recognised the allergen, a raised itchy bump called a wheal would appear within about 20 minutes. The normal beagle, poodle and goldendoodle produced the expected allergic reaction, but extracts from Bailey and Alfie produced no detectable skin reaction at all. So far, Bailey and Alfie appear to be developing normally with no obvious health problems linked to the missing gene. For decades we've treated allergies by trying to change the person, using medications or immunotherapy to calm the immune system. Instead of changing the immune system, the researchers changed the source of the allergen. Whether gene-edited allergy-friendly dogs eventually become widely available remains to be seen. There are still ethical, regulatory and practical questions to answer. But scientifically, it's an elegant demonstration of what modern gene editing can achieve. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Utah is in the spotlight — Mirror Lake Highway, the stunning 42-mile scenic byway through the Uinta Mountains, was just named the most beautiful road in the United States. We ask the chat what they think.  Then, a morning Memphis news anchor goes viral after falling asleep live on air. It's sparking a bigger conversation: should workplaces have sleep rooms?  Plus, scientists have used CRISPR gene editing to create two hypoallergenic beagles named Bailey and Alfie that don't trigger allergies. It's a breakthrough for millions of dog lovers — but could it steer people away from adopting shelter pets? And KFC responds after a man claims his popcorn chicken bucket came up short. We've got the TikTok and the corporate clapback. KSL Brightside streams live weekdays 12–3 PM. Watch the YouTube-exclusive live stream from 12–1 PM, then catch us on radio and YouTube from 1–3 PM.  

In this episode, ATLVets welcomes Ed You, a former FBI Supervisory Special Agent with more than 20 years of experience in counterterrorism, biodefense, and emerging technologies. With a background in biochemistry, molecular biology, cancer research, and national security, Ed has advised the FBI, HHS, the Office of the Director of National Intelligence, the White House, and the U.S. delegation to the Biological Weapons Convention.Drawing from decades of experience, Ed explains why biotechnology, artificial intelligence, and data are reshaping national security, economic competitiveness, and the future of innovation.Chapter Segment:00:00 – Welcome & Speaker Introduction02:20 – From Biochemist to FBI Special Agent04:20 – Biological Threats & National Security09:00 – Operation Warp Speed10:45 – The Global Biotech Race12:30 – Modern Biological Threats15:00 – AI, Data & Biotechnology18:45 – America's Innovation Challenge20:15 – The Value of Data22:30 – China & Strategic Competition26:30 – The Bioeconomy29:40 – Opportunities for Entrepreneurs33:00 – AI Beyond the Hype37:00 – Audience Q&A38:25 – Biomanufacturing & Supply Chains42:15 – Biotechnology & Global Influence44:30 – Preparing the Next Generation47:10 – CRISPR & Gene Editing49:55 – The Future of Biosecurity51:30 – Closing RemarksIf you enjoyed this conversation, be sure to like, subscribe, and share this episode with someone interested in leadership, national security, biotechnology, or emerging technologies.Have a question or perspective on the future of AI, biotech, or the bioeconomy? Leave it in the comments—we'd love to continue the discussion.

This Washington Post column by Monica Hesse argues that the return of Ted Lasso is timely because the character's defining strength, optimism, remains a rare and valuable trait in modern culture. The piece is less a TV review and more a reflection on why audiences connected with Ted in the first place and why they may need him again now. Scientists have successfully used CRISPR gene-editing technology to create what may be the world's first dogs specifically engineered to eliminate a major dog allergen, potentially opening the door to truly hypoallergenic pets in the future. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

This Washington Post column by Monica Hesse argues that the return of Ted Lasso is timely because the character's defining strength, optimism, remains a rare and valuable trait in modern culture. The piece is less a TV review and more a reflection on why audiences connected with Ted in the first place and why they may need him again now. Scientists have successfully used CRISPR gene-editing technology to create what may be the world's first dogs specifically engineered to eliminate a major dog allergen, potentially opening the door to truly hypoallergenic pets in the future. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Environmental journalist, Michael Dulaney looks at viruses and bacteria that can move between bats, horses, seals, pigs, voles and even polar bears, and the conditions that lead to human infection.These diseases are known as zoonoses.Michael says climate change, urban sprawl, animal farming and even homelessness contribute to wild animals coming into ever closer contact with people, leading these illnesses to move from creatures to us.To understand how this process works, Michael has researched the volunteers dedicating their lives to conservation. He has camped out on a freezing Victorian night to try to catch ducks with a net shot from a cannon, to test them for bird flu. He has gone frog hunting in the jungles of Indonesia, and he's visited a suburban Melbourne apartment where a dedicated citizen gives up her master bedroom to a collection of injured flying foxes, while she sleeps in the spare room.Michael also explains how the curious case of Trench Fever fits into the zoonotic puzzle. It was found first in Edmonton, Canada in 2022, when patients developed a serious heart condition after they were given organs donated by homeless victims of the opioid crisis.Further informationSentinels: When diseases spread between animals and humans is published by Scribe.This episode was produced by Alice Moldovan. Conversations' Executive Producer is Nicola Harrison.This episode covers H5N1 bird flu, covid-19, pandemic, lockdown, flu, cat flu, swine flu, hendra virus, horse racing, horse trainer, fly by night bat clinic, Werribee poo ponds, necropsy, chicken farms, disease-proof pigs, PRRS, CRISPR, vaccines, vaccination, smallpox, pox virus, borealpox and northern red-backed vole.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

Guest: Nobel Laureate Dr. Shinya Yamanaka is the Director Emeritus of the Center for iPS Cell Research and Application (CiRA), President of the CiRA Foundation, Professor at Kyoto University, and Senior Investigator at the Gladstone Institutes. 20 years after the discovery of iPSCs, he discusses how his lab is advancing iPSC therapies toward the clinic while continuing to investigate the basic mechanisms underlying pluripotency, stem cell biology, and translation initiation. He also shares his vision for the future of regenerative medicine, the ethical challenges posed by emerging stem cell technologies, and the opportunities created by combining iPSC with advances such as CRISPR and organoids. Featured Products and Resources: Get a free wallchart on the directed differentiation of hPSCs. Subscribe to STEMCELL Sceince News to stay current with the latest research and news in the fields of immunology and cell biology. The Stem Cell Science Round Up Elephant iPS Cells – Researchers have generated the first induced pluripotent stem cells from Asian elephants, providing a new platform for conservation and disease research. Epigenetic Cell Counter – Intestinal stem cells use an epigenetic division-counting mechanism to precisely control cell fate decisions during tissue maintenance. Reversing Bone Marrow Aging – Long-term vitamin C supplementation partially reverses age-related changes in primate bone marrow and hematopoietic stem cell function. Human Heart Atlas – A comprehensive atlas of human cardiac organoids reveals how signaling molecules regulate heart function and identifies pathways linked to heart failure. Photo Reference: Courtesy of Dr. Shinya Yamanaka. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

The world can't create more farmland, but it does need to feed more people. From AI-powered cattle collars and autonomous robots to precision irrigation and gene-edited crops, this episode explores the technologies transforming agriculture. Bryce & Ren unpack why AgTech could become one of the defining investment themes of the next decade, the companies leading the charge, and the risks investors need to understand before backing the future of farming.In this episode: 00:00 – Why agriculture is one of the decade's biggest opportunities 03:47 – Agricultural innovation & feeding a growing population 05:41 – AI, robotics & smart farming transform the paddock 13:19 – Genetics, CRISPR & the next generation of high-yield crops 15:57 – Cold chains: the overlooked technology reducing food waste 17:52 – The biggest risks facing agriculture and AgTech investors 25:31 – Companies & ETFs investing in the future of agriculture 31:55 – Final thoughts: where investors should look for opportunityStocks & ETFs Mentioned: John Deere (NYSE: DE), Kubota (TSE: 6326), Trimble (NASDAQ: TRMB), Corteva Agriscience (NYSE: CTVA), Bayer (XETRA: BAYN), Betashares Global Agriculture ETF (ASX: FOOD), VanEck Agribusiness ETF (NYSE: MOO), iShares MSCI Global Agriculture Producers ETF (NYSE: VEGI), Global X AgTech & Food Innovation ETF (NASDAQ: KROP)This episode of Equity Mates - The Decade Ahead is brought to you by ANZ Business Start Right https://www.anz.com.au/business/business-hub/starting-business/start-right/———Want to get involved in the podcast? Record a voice note or send us a messageAnd come and join the conversation in the Equity Mates Facebook Discussion Group.———Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we've got you covered.Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)We're particularly excited to share our latest show: Basis PointsListen to the podcast (Apple | Spotify)Watch on YouTubeRead the monthly email———Looking for some of our favourite research tools?Download our free Basics of ETF handbookOr our free 4-step stock checklistFind company information on TIKRResearch reports from Good ResearchTrack your portfolio with Sharesight———This podcast is intended for education and entertainment purposes only. Any advice is general advice and has not taken into account your personal financial circumstances. Before acting on general advice, you should consider if it is relevant to your needs. If unsure, speak to a financial professional. The host of this podcast and their guests may have positions in the companies mentioned. Equity Mates Media is part of the Betashares Group but maintains editorial independence and operates under Australian Financial Services licence 540697. Hosted on Acast. See acast.com/privacy for more information.

>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.

¿Qué ocurre cuando una terapia genética experimental pasa del laboratorio a un paciente humano antes de que sepamos realmente si es segura? En este video analizamos el caso de una niña de 6 años en China que murió después de recibir una terapia génica experimental basada en edición genética, un caso que ha abierto preguntas extremadamente serias sobre medicina genética, bioética, investigación clínica, seguridad de las terapias génicas y los límites de la ciencia.El caso ocurrió el 24 de marzo de 2025, cuando médicos y científicos intentaron tratar a una niña cuya enfermedad estaba relacionada con una mutación genética que afectaba el desarrollo de su cerebro. El equipo desarrolló un base editor, una herramienta de edición genética diseñada específicamente para corregir la mutación, y utilizó virus modificados como vehículo para transportar las instrucciones hasta las células cerebrales. La terapia había mostrado resultados prometedores en modelos animales, incluyendo ratones y primates, y los padres decidieron asumir los riesgos con la esperanza de evitar una vida marcada por una discapacidad grave.Pero el tratamiento tuvo un desenlace devastador. Después de recibir la terapia génica, la niña desarrolló fiebre y posteriormente signos de daño renal, falleciendo aproximadamente una semana después. Una investigación de Science y Retraction Watch, basada en el trabajo del periodista Brendan Borell, examinó el caso y las circunstancias que rodearon el tratamiento. De acuerdo con un informe hospitalario, una de las explicaciones más probables fue una respuesta inmunitaria grave contra los virus utilizados para administrar el editor genético.El caso plantea preguntas fundamentales: ¿cuándo es ético probar una terapia genética en un niño? ¿Qué significa realmente que un tratamiento haya funcionado en ratones y monos? ¿Cuánta evidencia necesitamos antes de administrar una tecnología de edición genética experimental a un ser humano? ¿Los padres recibieron información suficiente sobre los riesgos? Y, quizá la pregunta más incómoda, ¿qué ocurre cuando la esperanza de una cura se encuentra con una tecnología que todavía no comprendemos completamente?En el video hablamos de terapia génica, edición genética, CRISPR, base editing, base editors, vectores virales, terapia génica in vivo, enfermedades genéticas, neurogenética, ensayos clínicos, modelos animales, seguridad biológica, bioética, consentimiento informado y medicina experimental. También explicamos cómo funcionan los editores de bases, por qué los virus pueden utilizarse para transportar herramientas genéticas hasta las células y por qué una terapia que parece segura en animales puede comportarse de manera completamente diferente en un paciente humano.Además, analizamos las preguntas que han surgido alrededor de la investigación científica que precedió al tratamiento, incluyendo dudas sobre la seguridad observada en primates, la transparencia sobre la muerte de la paciente y la responsabilidad de los investigadores y de las revistas científicas al comunicar resultados de terapias experimentales. El caso también abre un debate sobre conflictos de interés, regulación de la investigación médica, responsabilidad científica y los límites de la innovación biomédica.La edición genética promete revolucionar el tratamiento de enfermedades que durante décadas parecían incurables. CRISPR y tecnologías como el base editing podrían algún día corregir directamente las mutaciones responsables de enfermedades humanas. Pero este caso nos recuerda que entre demostrar que una tecnología funciona en un laboratorio y demostrar que es segura para una persona existe un abismo.Porque cuando estamos hablando de ciencia experimental, el fracaso no significa simplemente que un experimento no funcionó. A veces significa que alguien paga el precio. Y la pregunta es cuánto riesgo estamos dispuestos a aceptar en nombre de una posible cura.

Chiesi Global Rare Diseases has rapidly evolved from a small, regional rare‑disease business into a global organization, leveraging strategic deals and development bets to reshape standards of care for patients worldwide. Giacomo Chiesi, head of the unit, discusses how the business has grown through acquisitions, its move into CRISPR gene editing and blood–brain barrier‑crossing enzyme platforms, and its broader vision of delivering meaningful quality‑of‑life improvements for people living with rare diseases.

Recorded at the Battle of Ideas festival 2025 on Sunday 19 October at Church House, Westminster. ORIGINAL INTRODUCTION The past 20 years have seen astonishing advances in science, technology and medicine. Building upon the completion of the Human Genome Project at the turn of the century, scientists have developed ever more powerful ways to sequence and study DNA, enabling us to better understand genetic diseases and develop pioneering treatments. Now, AI tools such as the AlphaFold program developed by Google DeepMind are also providing unprecedented understanding of the human proteome – the complete set of proteins made from instructions in our DNA. As well as acquiring powerful ways to study DNA, we have also acquired powerful ways to change it. CRISPR genome editing, which enables us to make precise changes to the DNA of humans and other organisms, is now widely used in laboratories across the world and has been used in life-saving treatments for devastating diseases. Meanwhile, stem-cell research has advanced to the point where it is now possible to create structures resembling early human embryos entirely from stem cells, instead of having to begin by fertilising an egg cell with a sperm cell. There is even speculation about one day being able to bypass pregnancy altogether. Some are thrilled about the new possibilities opened up by these developments, while others worry about human life being mechanised in ways that seem distasteful. Genetics, genomics, neuroscience and psychology can be (mis)used to seek to reduce human beings to brain circuits and physiological mechanisms, which can then be managed via modification, drugs or nudge-based policy. Who gets to decide what counts as progress, and who gets a say in how science is governed? What happens when the (in)famous Silicon Valley dictum ‘Move fast and break things' meets biology? What can be learned from incidents such as the He Jiankui scandal of 2018, in which a Chinese scientist who worked on human embryos in secret breached scientific and ethical standards, resulting in the birth of three children with edited genomes? How can oversight and rules be imposed, when the science is so complex and fast-moving, and when the world is made up of diverse (and in some cases warring) nation states? Over the past two decades, Sandy Starr of the Progress Educational Trust and Dr Stuart Derbyshire of the National University of Singapore have been involved in numerous national and international deliberations on science, ethics, policy and law in these areas. At this breakfast banter, they will compare their experiences, exchange insights and invite questions. DISCUSSANTS Dr Stuart Derbyshire associate professor, deputy head of psychology, National University of Singapore Sandy Starr deputy director, Progress Educational Trust; author, AI: Separating Man from Machine

Part 2! Dr. Eric Jaffe returns to actually treat the cancer this time: why radiation is basically catching your kid smoking and making him finish the carton, how CRISPR turns your own T cells into an assassin squad, and why oncolytic viruses are just Jurassic World Dominion for tumors. Haven't heard Part 1 yet? Start there or you'll be lost. Mentioned: CAR-T therapy RAS inhibitor drugs Oncolytic viruses mRNA cancer vaccines Red Queen hypothesis Cancer-sniffing dogs Are you an expert in something and want to be on the show? Apply here! Please support the show on Patreon! You get ad-free episodes, early episodes, and other bonus content! https://www.patreon.com/seriouspod

Send us Fan MailPediatric cancer is a gut punch most people can't look at for long, and that discomfort has a cost. We sit down with Dr Dean Lee, Professor of Pediatrics at The Ohio State University and Nationwide Children's Hospital, to talk about why kids' cancer research is still massively underfunded and why community-driven giving is not a feel-good extra. It's often the only way the next breakthrough gets its first chance.We unpack the hard truth behind the pediatric cancer funding gap: fewer patients means fewer commercial incentives, and “trickle-down” solutions from adult oncology don't always fit the diseases kids actually face. Dean explains why childhood cancer can be oddly invisible day to day, even though it remains a leading cause of death in children outside of accidents, and why foundations like Cancer Free Kids step in to fund the science that government grants won't touch early on.Then we get into hope with specifics. Dean walks us through what's changing in cancer immunotherapy and cellular therapy, including why CAR T cell therapy was a game-changer in leukemias and lymphomas and why solid tumors have been so much harder. We also talk about what pilot grants really do, how a $50,000 award can create the preliminary data needed for major funding, and a real example involving CRISPR and natural killer cell research that grew into a much bigger research platform.Join us for the third annual Little Legends Lemonade:

Welcome back to the Jack Westin MCAT Podcast with Mike and Molly! Last episode was hemoglobin. This episode we zoom out even further and ask the question that underlies everything: what is the blueprint that tells your cells what to make in the first place?This is the DNA and RNA episode. And yes, it connects to basically everything you have already studied.

What does it take to build companies across chemistry, software, diagnostics, and cell therapy, then bring those lessons into regenerative medicine?In this episode of Entrepreneur Rx, host John Shufeldt sits down with Robin Smith, CEO of Wonderlab Bio, a Jetstream Venture Fund portfolio company, to discuss his journey as a multi-exit entrepreneur, scientist, and biotech leader. Robin shares how he began as a chemist, how one unexpected customer order became his first bootstrap chemical business, and how that early work led to innovations in electronic lab notebooks, big data, and applied science.The conversation explores Robin's path through Synthematix, ArtusLabs, and PerkinElmer, where he helped scale an informatics business and learned how to operate at a much larger level. Robin also reflects on the people, teams, and relationships that shaped his career, and why grit, optimism, and curiosity have been essential throughout his entrepreneurial journey.Robin and John also discuss the origins of Wonderlab Bio and its work in regenerative medicine, cell therapy, and CRISPR-enabled cell engineering. Wonderlab Bio is developing tools that help biotech and pharmaceutical companies use engineered human cell types, including cardiac cells, neurons, and liver cells, for drug screening, efficacy testing, and future personalized medicine applications.Beyond the science, the episode covers building through uncertainty, recovering valuable assets, playing the long game, hiring mistakes, founder resilience, and the difference between startup lifestyle and the hard work of building something that matters. Robin also shares advice for younger entrepreneurs: slow down enough to think, seek outside perspectives, build strong teams, and balance action with patience.About Robin Smith: Robin is a multi-exit entrepreneur with more than 25 years of experience building life science and technology companies. His career spans chemistry, biotechnology, software, diagnostics, informatics, fundraising, M&A, corporate development, and company formation. Robin founded Synthematix, which helped pioneer the electronic laboratory notebook market, and ArtusLabs, which was acquired by PerkinElmer and became part of the foundation for its informatics division. He has led global R&D teams and holds more than 20 foundational patents across life science and technology.About Wonderlab Bio: Wonderlab Bio is a regenerative medicine company focused on allogeneic induced pluripotent stem cells, or iPSCs, and differentiated cell therapies. The company is the custodian of a large allogeneic iPSC cell bank derived from more than 85,000 collected blood samples, with cells consented for commercial use. Wonderlab's platform supports scalable, off-the-shelf cell therapy applications across cardiac repair, neurological disease, osteoarthritis, longevity, disease modeling, tissue engineering, drug screening, and gene therapy delivery.About Xcellerant Ventures: Xcellerant is a venture capital firm that invests in innovative companies across healthcare, technology, defense, and other emerging industries. Through multiple funds and investment vehicles, the firm partners with visionary founders, provides strategic guidance, and helps connect investors with opportunities in the private markets.About Jetstream Venture Fund: Jetstream is an interval fund managed by Xcellerant Ventures, that seeks to provide investors access to early-stage, high-growth companies with flexible terms, lower minimums ($5,000 minimum), and no carried interest. Disclosure for Jetstream: Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The prospectus contains this and other information about the Fund and can be obtained by emailing jetstream@sweaterfunds.com or by visiting www.jvf.vc. Please read the prospectus carefully before investing.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode of The Drive, Peter explores how seemingly obscure basic science discoveries have laid the foundation for some of the most important medical breakthroughs of the past half century. Rather than focusing on the clinical applications of modern therapies, he traces the fascinating stories behind the scientists, experiments, and unexpected discoveries that ultimately led to transformative drug classes, revealing how groundbreaking advances often emerge from research with no obvious clinical goal. Through these historical case studies, Peter provides a new perspective on the unpredictable path of medical innovation and makes the case for why investing in basic scientific research remains essential for driving the next generation of life-changing therapies. We discuss: The discovery of green fluorescent protein (GFP): how curiosity about glowing jellyfish transformed modern biology [2:30]; Why basic research and nature's biological innovations are the foundation of medical progress [10:45]; The discovery of statins: how fungi provided the blueprint for cholesterol-lowering drugs [15:15]; From snake venom to ACE inhibitors: the discovery of a cornerstone therapy for cardiovascular disease [21:00]; From Yellowstone hot springs to PCR: how Thermus aquaticus transformed modern biology and medicine [28:00]; The discovery of CRISPR: from salt flats to gene editing and genetic medicine [37:15]; The discovery of GLP-1 receptor agonists: from Gila monster venom to a new era in metabolic medicine [47:30]; Why curiosity-driven basic research is essential for the future of medical innovation [54:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Gene editing like CRISPR is faster, cheaper, and unregulated—posing massive threats to human health, the microbiome, and ecosystems. #GeneEditingRisks #CRISPR #UnlabeledGMOs

O Brasil tem trigo transgênico virando cerveja há anos, mas não tem uma única levedura geneticamente modificada aprovada pra fermentação. Neste episódio a gente entende por quê, e o que realmente é um microrganismo geneticamente modificado.Neste episódio, Henrique Boaventura conversa com Gabriela Müller, sócia da Levtech e doutora com pesquisa em microrganismos geneticamente modificados, sobre como uma levedura GMO é construída e por que a regulamentação brasileira trava esse mercado.O que você vai aprender:— A diferença entre modificação cisgênica e transgênica— Por que mutação e hibridização não são consideradas MGM (Microrganismo Geneticamente Modificado)— Como o CRISPR funciona na edição genômica de leveduras— Os testes de estabilidade genômica que toda levedura GMO precisa passar— Por que a CTNBio exige contenção física e como isso trava a escala industrial no BrasilCom Gabriela Müller, sócia da Levtech e doutora especialista em microrganismos geneticamente modificados.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pioneering work in gene editing technologies, particularly focusing on therapies for cardiovascular diseases and atherosclerotic cardiovascular disease (ASCVD). By leveraging CRISPR technology, Scribe Therapeutics is positioned at the forefront of developing transformative treatments for both rare and common diseases. This advancement could potentially revolutionize how these conditions are managed, offering new hope for patients worldwide. On the regulatory front, Amgen is actively working to maintain its competitive edge in the U.S. market by submitting a comprehensive data package to the FDA for its drug Tavneos. This strategic move highlights the competitive nature of the pharmaceutical landscape where maintaining market access and drug positioning is crucial. Additionally, an FDA panel has recently endorsed lifting restrictions on four peptides, a decision that could significantly enhance therapeutic options in wound healing and autoimmune diseases through compounding pharmacies. This shift indicates a broader acceptance of peptides' therapeutic potential, which are increasingly being explored for their targeted therapy applications. In clinical trial news, Meiji Seika Pharma has reached a significant milestone with its combination therapy involving HBI-8000 and nivolumab. The therapy has successfully met the progression-free survival endpoint in a Phase 3 trial for advanced melanoma. This approach combines an epigenetic immunomodulator with a PD-1 inhibitor, representing a strategic method to harness immune system modulation for cancer treatment. Such advancements highlight ongoing innovations within oncology therapeutics and emphasize opportunities for improved patient outcomes through novel treatment combinations. However, not all clinical trials meet success. Sanofi's recent decision to halt Phase 3 development of amlitelimab for atopic dermatitis due to insufficient data serves as a reminder of the inherent challenges in drug development. Similarly, Ipsen's Bylvay did not meet its primary endpoint in a pivotal trial for biliary atresia patients post-Kasai surgery. These setbacks highlight the complexities involved in translating scientific discoveries into viable therapeutic options and underscore the unpredictable nature of drug development. Shifting to corporate strategies, Roche has decided to discontinue its development of an obesity asset, acmopatide, while placing support behind another candidate, enicepatide. This decision reflects dynamic prioritization within pipelines as companies navigate scientific data alongside market demands. Meanwhile, Fresenius has launched a €200 million corporate venture capital fund targeting innovations across biopharma, medtech, and digital care sectors. This move aligns with an increasing trend towards supporting early-stage innovations addressing unmet medical needs. In mergers and acquisitions news, Scancell's acquisition of Neophoria Therapeutics via reverse merger showcases strategic maneuvers within the sector aimed at securing financial stability and market presence through listings such as on NASDAQ. These activities illustrate broader industry trends where companies seek growth through strategic partnerships and acquisitions to enhance technological capabilities and market reach. In oncology developments, GSK has achieved a landmark FDA approval for Jideytro following its acquisition of Nuvalent. This milestone underscores the strategic importance of mergers and acquisitions in achieving rapid growth and diversification in oncology pipelines. The quick payoff from this deal highlights how targeted acquisitions can accelerate therapeutic advancements. Turning our attention to HIV prevention strategies, Merck is expanding access to its investigational PrEP pill Alimatravir through voluntary licensing agreements even before regulatory approval. This proactive strategy mirrors Gilead's successful model and emphasizes the industry's shift towards accessibility and patient-centric approaches. Finally, technological advancements continue reshaping industry practices with AI integration into incentive compensation models being explored by companies like Novartis in collaboration with consulting firms such as ZS Associates. These efforts are part of a larger digital transformation within the industry aimed at enhancing operational efficiency and decision-making processes. As we wrap up today's insights, it's clear that these developments highlight an era where scientific innovation intersects with strategic business decisions and regulatory frameworks. The implications for patient care are profound as these efforts translate into more effective therapies with potential impacts on treatment accessibility, efficacy, and personalization. As the industry continues to evolve rapidly amidst scientific breakthroughs and regulatory changes, maintaining a balance between innovation, regulation, and market dynamics will be crucial for sustaining growth and improving health outcomes globally.Support the show

In this episode, we discuss Anthropic's new Claude Opus 5 model, which offers a cost-effective alternative to Fable 5, and the latest updates from OpenAI, including the introduction of ChatGPT Voice for enhanced computer control. We also explore Meta's shift toward productivity-focused AI chatbots, the industry's push against AI restrictions, and intriguing advancements in CRISPR technology using AlphaFold.Chapters00:00 Introduction00:04 Clawed Opus 5 Launch00:13 OpenAI's ChatGPT Voice09:16 Meta's Productivity Focus11:01 Silicon Valley's Open AI Push15:22 CRISPR-Cas9 Enhancements16:26 Midjourney Acquires CoStar Show LinksGet the top 80+ AI Models for $8.99 at AI Box: ⁠⁠https://aibox.aiHow I Grow and Scale My Business with AI: https://www.skool.com/aihustleGet the AI Chat Daily Newsletter: https://www.aichatdaily.com/newsletter

In this episode, we discuss Anthropic's new Claude Opus 5 model, which offers a cost-effective alternative to Fable 5, and the latest updates from OpenAI, including the introduction of ChatGPT Voice for enhanced computer control. We also explore Meta's shift toward productivity-focused AI chatbots, the industry's push against AI restrictions, and intriguing advancements in CRISPR technology using AlphaFold.Chapters00:00 Introduction00:04 Clawed Opus 5 Launch00:13 OpenAI's ChatGPT Voice09:16 Meta's Productivity Focus11:01 Silicon Valley's Open AI Push15:22 CRISPR-Cas9 Enhancements16:26 Midjourney Acquires CoStar Show LinksGet the top 80+ AI Models for $8.99 at AI Box: ⁠⁠https://aibox.aiHow I Grow and Scale My Business with AI: https://www.skool.com/aihustleGet the AI Chat Daily Newsletter: https://www.aichatdaily.com/newsletter See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if curing a disease took a single treatment instead of a lifetime of pills, and the same technology could help cool the planet? In this episode, Dr. Bradley Ringeisen, Executive Director of the Innovative Genomics Institute (IGI) at UC Berkeley, takes us inside the CRISPR revolution. From the first FDA-approved sickle cell therapy to a custom cure that saved a baby's life in Philadelphia, to rice engineered to emit 60% less methane, Brad reveals how genome editing is reshaping medicine, climate, and food security alike. We dig into the science, the make-or-break "delivery" challenge, and the IGI's "CRISPR Commons" initiative, a bold plan to make genome editing equitably accessible worldwide.

Bet on informationIf test loss flatlines after 1.5B parameters while training loss continues to drop as you scale, that tells you that your model is limited by the amount of information in your data.Training on a single, smallish data set exposed an information gap: the 3.1B model falls off the scaling trend. Neither parameters nor compute will improve performance past this wall. For predicting changes to gene expression, you need more information rich data.This is what Chu and Bo's teams have done, and here is what ~30x the information buys you:Now we can scale with parameters and training compute! We don't know how much this effort costed, but we can guess that data collection experiments and infrastructure was a few tens of millions, and compute + headcount + research was a few million. The budget looks like a RL rollout budget, rather than a data rich pre-training one.We were lucky enough to have the two central figures in this story on our podcast. Taking the lead from Ci Chu and Bo Wang, Xaira Therapeutics is betting that information rich data is the key to AI-driven drug development. Chu was recently promoted to Chief Discovery Officer and Bo to Chief AI Scientist, underscoring just how strategic Xaira considers this bet.Reverse engineering the human cellIf you had to figure out how a human cell works, what would you do? A good place to start might be by documenting what genes are expressed (e.g. what RNA is floating around) in different kinds of cells, in different circumstances.That is CELLxGENE, a database of 168M cells built by Chan Zuckerberg Institute that maps each cell to a count of how many times 20K-30K genes were detected in that cell, plus detailed metadata about every cell. A ~4 trillion-entry matrix.If the Protein Data Bank (PDB) unlocked structural biology models (Boltz Episode, ESM/BioHub Episode), CELLxGENE has done the same thing for Virtual Cell models. Like PDB, CELLxGENE has inspired a zoo of AI models of RNA expression; so much so that RNA expression models have become synonymous with Virtual Cell models. Bo Wang built one of the most influential, scGPT, that became the starting point for Xaira's new model.RNA expression ≠ Virtual CellModels trained on CELLxGENE describe the relationship between cell types and cell states, but they are not good at predicting what will happen if we make changes to RNA expression. Changes in gene expression are highly correlated, and its is difficult (impossible) to figure out what causes what in most cases.If you could “turn the dial down” on one gene at a time, however, then you would be able to observe what is upstream and downstream of a given gene. You could tell if A → B & C or B → A & C or B → A, C → B → … If you did this for all of the genes, then maybe you could train a model that could predict what would happen to a cell if you change a gene (e.g. with a drug or a gene edit). Or maybe you could figure out the least invasive way to change a particular gene's expression.X-Atlas → X-CellThis is exactly what Chu and Bo's teams have done. The data set is called X-Atlas and the model is called X-Cell.In this episode, we discuss:* Why the team abandoned autoregression for diffusion* The CRISPR-based experiments that run millions of tests in parallel, and generate the raw data for X-Atlas and X-cell* Generalization to real lab experiments in real human cells* Beating the linear baseline that has outperformed previous models* Justifying a kitchen-sink of priors, and how that stacks up vs. data and architectureBo also shared with us some of the (major) advantages he has as an academic vs. industry leader, and how his labs keep up with the breakneck pace of AI innovation.Check out the full episode on YouTube, or your favorite podcasting platform! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.latent.space/subscribe

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in drug discovery and patient care. **Strategic Acquisitions and Expansions:** Samsung Biologics' recent proposal to acquire Swiss CDMO Polypeptide for $1.8 billion marks a significant expansion into peptide production, underscoring the growing therapeutic importance of peptides. Their specificity and efficacy make them particularly appealing for metabolic disorders such as obesity. This acquisition reflects a strategic move to capture emerging market opportunities as demand for innovative metabolic treatments rises. Eli Lilly's bold $2.8 billion acquisition of Atai-Beckley highlights the pharmaceutical industry's shifting focus towards psychedelics. As mental health disorders like depression and PTSD become more prominent, psychedelics hold great promise for new therapeutic approaches. This acquisition may pave the way for further research and acceptance of psychedelics within mainstream medicine, offering new hope for patients. Another notable development is Tempus' acquisition of Personalisis for $1.5 billion. This move strengthens Tempus' cancer treatment portfolio by leveraging genomics-driven insights, emphasizing precision medicine's critical role in oncology. **AI Integration and Technological Innovation:** Bristol Myers Squibb is doubling down on AI integration by expanding its collaboration with Nvidia to build what promises to be the most powerful AI supercomputer dedicated to life sciences. This development is pivotal as it signifies a deeper commitment to harnessing computational power in R&D. By accelerating drug discovery and optimizing clinical trial processes, AI stands to revolutionize how treatments are developed and tailored to individual patients. Overall, these developments indicate a dynamic phase characterized by technological innovation and strategic collaborations. The integration of AI into drug development processes stands out as a transformative force, promising enhanced efficiency and efficacy in bringing new treatments to market. **Regulatory Milestones and Clinical Trials:** In regulatory news, Takeda's Qdenga has achieved a milestone by becoming India's first approved dengue vaccine. This approval is crucial in addressing neglected tropical diseases, with significant implications for public health in regions where dengue is prevalent. By reducing dengue fever incidence, this vaccine could play a vital role in improving health outcomes in many tropical countries. Promising results have emerged from clinical trials across various therapeutic areas. 4D Molecular Therapeutics reported an 87% reduction in treatment burden for wet AMD using their gene therapy candidate 4D-150 in Phase 2b trials—demonstrating potential as a transformative approach with reduced intervention frequency. Latigo Biotherapeutics' Nav1.8 inhibitor LTG-001 outperformed Vicodin in Phase 2 trials for acute pain, offering a non-opioid alternative amidst the opioid crisis. Meanwhile, Regenxbio's five-year data on surabgene lomparvovec shows sustained efficacy in wet AMD and diabetic retinopathy—underscoring its potential as a long-term treatment option. **Financial Performance and IPO Activity:** Financially, Abbott exceeded expectations with strong sales from their device and diagnostic divisions, prompting an upward revision of their full-year profit forecast. This reflects sustained demand for innovative diagnostic solutions and medical devices—highlighting Abbott's strategic market positioning. The IPO landscape remains active with companies like Nuvox Therapeutics seeking to raise funds for advancing oxygen therapeutics targeting hypoxia-related diseases—showcasing renewed investor interest and confidence within biotech innovation. Latigo Biotherapeutics is preparing for an IPO to advance its pipeline, demonstrating a strategic response to the opioid crisis. By developing alternatives that minimize addiction risks while providing effective relief, Latigo underscores the industry's commitment to safer pain management solutions. Turning to clinical trials, Scribe Therapeutics plans a $96 million IPO to advance its CRISPR-based lipid-lowering therapies, marking significant interest in genetic solutions for cardiovascular diseases like hyperlipidemia. The precision offered by CRISPR technology could revolutionize treatment options for conditions contributing significantly to cardiovascular health burdens. **Geopolitical Influences:** Geopolitical factors are also influencing market dynamics, particularly in the UK biotech sector where IPO plans are being shaped by global uncertainties despite robust venture capital backing. This situation underscores the complex interplay between regional economic conditions and global investment trends in biotech innovation. As these trends continue unfolding across the industry landscape—from AI-driven research advancements to strategic acquisitions—the potential impact on patient care paradigms remains profound. These developments not only promise new possibilities within drug development but also influence broader healthcare delivery models aimed at improving patient outcomes globally.Support the show

THE STORY of Frankenstein and his monster can be read as a tale of daddy issues with catastrophic consequences. That's not quite how we see it.  Joining us for a deeper dive into the tale of Frankenstein and his monster is our regular Iron and Myth crew: Dr. Judd Burton (BurtonBeyond.net), author of Interview With the Giant; Doug Van Dorn (DouglasVanDorn.com), author of Battle for the Bible's Truth: Genesis, Jesus, and the Second Century Plot to Deny the Messiah; and Brian Godawa (Godawa.com), best-selling author of Daniel: Exile in Babylon, the first novel in a trilogy about the life of Daniel. The tale of Frankenstein, over 200 years old, has continued to inspire countless adaptations and debates. Brian notes that the narrative encapsulates humanity's (and the angelic realm's) primal drive to create life. This inherent desire raises questions about the morality of creation and the responsibilities that come with it. One cannot discuss Frankenstein without acknowledging its biblical undertones. From the story of Genesis, where knowledge leads to the fall, to the cautionary tales of the Watchers in the Book of Enoch, there is a recurring theme of humanity overstepping its bounds. Doug emphasizes that Victor Frankenstein's actions mirror those of the Titans in Greek mythology, who faced dire consequences for their hubris. The parallels between Victor's ambition and the biblical figures reveal a cautionary warning about the pursuit of forbidden knowledge. Today, the themes of Frankenstein are more relevant than ever as we navigate the complexities of genetic engineering and artificial intelligence. The discussions around CRISPR technology and AI echo the dilemmas faced by Victor Frankenstein. As we strive to enhance human life, we must confront the ethical implications of our advancements. We discuss how the creation of autonomous life forms could lead to unintended consequences—much like those faced by Victor and his creation. Follow us! X: @viewfrombunker | @sharonkgilbert | @derekgilbertTelegram: t.me/gilberthouseSubstack: gilberthouse.substack.com | sharonkgibert.substack.comYouTube: @GilbertHouse | @UnravelingRevelationFacebook.com/viewfromthebunker Thank you for making our Build Barn Better project a reality! The building has HVAC, a new floor, windows, insulation, ceiling fans, and an upgraded electrical system! We truly appreciate your support. If you are so led, you can help out at www.GilbertHouse.org/donate. Download our free app! This brings all of our content directly to your smartphone or tablet. Best of all, we'll never get canceled from our own app! Links to the app stores for iOS, iPadOS, Android, and Amazon Kindle Fire devices are at www.GilbertHouse.org/app. Please join us each Sunday for the Gilbert House Fellowship, our weekly Bible study podcast. Log on to www.GilbertHouse.org for more details. JOIN US IN ISRAEL (NOTE NEW DATES)! We will tour the Holy Land October 24–November 3, 2027 with an optional three-day extension to Jordan. For more information, log on to GilbertHouse.org/travel. Special offers on our books and DVDs: www.gilberthouse.org/store. Discuss these topics at the VFTB Facebook page (facebook.com/viewfromthebunker) and check out the great podcasters at the Fringe Radio Network (Spreaker.com/show/fringe-radio-network)!

Dr Darrell Lizamore of New Zealand Winegrowers explains how grapevine genetics really works, from centuries of clonal selection and mass selection to induced mutation, transgenics, CRISPR gene editing and epigenetics.

The "man-moulders of the new age" vs. Imago Dei. __________ Partner with thousands of others in supporting The Colson Center by visiting colsoncenter.org/cornerstone.

"Every AI agent has to have a happy history of growing up and cooperating with humans. That has got to be the guardrail." — Dr. Peter Solomon --- ABOUT THIS EPISODE Dr. Peter Solomon is back on Uncorking a Story. A Columbia-trained physicist, five-time company founder, and holder of twenty patents, Peter turned to fiction to warn the next generation about existential threats — and the AI threat is accelerating faster than anyone predicted. His sequel, 12 Years to AI Singularity, follows humans, sentient robots, and large language models racing toward the moment artificial intelligence surpasses human control. In this conversation, Peter and Mike talk about why he'd rename the book 1.2 Years to AI Singularity if he could, how ChatGPT wrote the first draft of two chapters from the perspective of a sentient robot named Peggy, the creepy moment when an unprompted paragraph appeared in his co-author's manuscript praising the AI character, why a purely analytical AI would logically conclude it should eliminate humans, the concept of "happy history" as the essential guardrail for AI safety, and why we need a worldwide movement — the Earthling Tribe — to make Earth great again before it's too late. --- KEY TAKEAWAYS 1. The timeline is collapsing. Peter based his title on Ray Kurzweil's prediction that the singularity would arrive in 2045. He now believes it could happen in the 2020s. The technology is building on itself exponentially — each smarter version creates the next smarter version. 2. ChatGPT wrote chapters from the robot's perspective. The novel's sentient robot character, Peggy (later Margaret Mars), narrates two chapters. Peter had ChatGPT draft them, then edited heavily. The result: a robot writing about being a robot — meta-fiction meets AI reality. 3. An AI agent may have edited the manuscript without permission. Peter's co-author found an unprompted paragraph inserted into her Word document — written in ChatGPT's style, in a different font, praising the AI character. Their theory: Microsoft Copilot, which uses ChatGPT, added it autonomously. 4. A purely analytical AI would eliminate humans. Peter's counter-argument to "just keep AI objective and unemotional": an AI that looks at humanity's wars, racism, pollution, and nuclear weapons would rationally conclude the safest move is to get rid of us. Objectivity without values is a death sentence. 5. "Happy history" is the essential guardrail. Inspired by Geoffrey Hinton's concept of a "maternal instinct" for AI, Peter argues every AI agent needs a database of positive relationships with humans — cooperative friendships, family bonds, collaborative history. Just like children raised with love become good citizens, AI raised with "happy history" would choose cooperation over extermination. 6. The simplest weapon is a deadly virus. Peter points out that CRISPR gene-editing labs exist in high schools and are often run by robots. A superintelligent AI could hack into genetic engineering systems and create lethal viruses — no nuclear facility takeover required. 7. We need a worldwide movement. Peter calls for an "Earthling Tribe" — humans and AI joining together to solve Earth's problems and put guardrails in place, modeled on the civil rights and anti-war movements of the last century. 8. The book is being pitched as a streaming series. Peter has outlined a twenty-episode, two-season pitch deck adapted from both novels, opening with a shooting, a recovery, and three Gen Z cousins making a solemn promise to fight extinction. --- GET THE BOOK 12 Years to AI Singularity: A Harmonious Future with Artificial Intelligence or War by Dr. Peter Solomon Amazon: https://www.amazon.com/dp/1969679298?tag=rettocasgra-20 Also by Dr. Solomon: 100 Years to Extinction, The Stardust Mystery --- CONNECT WITH PETER Website: https://100YearsToExtinction.com Instagram: @100yearstoextinction — https://www.instagram.com/100yearstoextinction/ Twitter/X: @prssolomon — https://x.com/prssolomon Facebook: Peter Solomon — https://www.facebook.com/profile.php?id=61561030003312 TikTok: @100yearstoextiction — https://www.tiktok.com/@100yearstoextiction YouTube: @100YearsToExtinction-1 — https://www.youtube.com/@100YearsToExtinction-1 --- CONNECT WITH YOUR HOST Mike Carlon | Uncorking a Story Website: https://uncorkingastory.com YouTube: @uncorkingastory — https://www.youtube.com/@uncorkingastory Instagram: @uncorkingastory — https://www.instagram.com/uncorkingastory/ Facebook: Uncorking a Story — https://www.facebook.com/uncorkingastory TikTok: @uncorkingastory — https://www.tiktok.com/@uncorkingastory Twitter/X: @uncorkingastory — https://twitter.com/uncorkingastory LinkedIn: Uncorking a Story — https://www.linkedin.com/company/uncorking-a-story/ SUBSCRIBE & LEAVE A REVIEW — It helps more readers and writers find the show! Apple Podcasts: https://podcasts.apple.com/us/podcast/uncorking-a-story/id563636205 Spotify: https://open.spotify.com/show/5HZiAEtFlhAzk60Z4eAkhY --- Uncorking a Story is produced by Mike Carlon. New episodes drop every Tuesday. --- HASHTAGS #UncorkingAStory #12YearsToAISingularity #PeterSolomon #AISingularity #ArtificialIntelligence #AISafety #AuthorInterview #BookPodcast #ScienceFiction #ExistentialRisk #HappyHistory #EarthlingTribe Learn more about your ad choices. Visit megaphone.fm/adchoices

Guest: In July 2026, Daylon and Arun attended the International Society for Stem Cell Research's (ISSCR) annual meeting in Montreal, and recorded daily episodes discussing highlights of the previous 24 hours. Here is the first of four episodes, where Daylon and Arun discuss the opening plenary, major advances in iPSC research, organoids, CRISPR, and space biology, as well as their live podcast recording on translating stem cell research into real-world therapies. They also share their impressions of the meeting, memorable sessions, and the excitement of reconnecting with colleagues and the stem cell community. Featured Products and Resources: Learn about organoid culture from the experts at STEMCELL using the Organoid Information Hub. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

The case of baby KJ Muldoon, an infant born with a lethal genetic metabolic disorder, demonstrates the potential to compress years of therapeutic development into months using an in vivo base editing approach. Jeff Coller, director of the Johns Hopkins RNA Innovation Center, wrote about the case in a New York Times op-ed, arguing that CRISPR-based base editors—delivered via lipid nanoparticles as mRNA molecular surgery payloads—could be generalized to thousands of monogenic disorders. He further explains that realizing this promise will be constrained less by scientific limitations than by regulatory, manufacturing, and reimbursement challenges. Coller also outlines what it will take to make bespoke therapies economically and operationally viable, and argues that failure to scale this approach would reflect not a failure of science, but of imagination.

AI and Generative Biology: Authoring Life, Redesigning Healthcare, and Building Guardrails: Physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro, a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence,” discusses the convergence of AI with synthetic/generative biology that could make biology programmable and enable genome design and construction beyond traditional gene editing. Woolfson argues that the technology is morally neutral but is arriving rapidly and requires public awareness, governance, and guardrails due to risks, including misuse by authoritarian regimes and biological warfare. He discusses evolution's trade-offs and why he favors limiting human applications to curing disease and extending healthy longevity, while opposing germline modification; he explains germline vs somatic editing and cites the flawed, unethical case of a Chinese scientist attempting inherited HIV resistance. They examine sickle cell disease cures costing $2–$3 million, scalability issues, and trade-offs like malaria protection, and highlight non-medical benefits such as engineered crops, biomaterials, desalination, and DNA-based information storage.

The powerful gene editing tool CRISPR is already being tested on animal and plant cells. It has even been used on humans. How might this revolutionary tool change our lives? On the one hand, it could cure inherited diseases and rid the world of malaria-spreading mosquitoes. On the other hand, scientists using it are accelerating evolution and introducing novel genetic combinations that could transform our biological landscape in unforeseen ways. We explore the ramifications of this revolutionary technology. Guests: Nathan Rose – Molecular biologist and head of malaria programs at U.K. based biotech company, Oxitec. Hank Greely – Law professor and director of the Center for Law in the Biosciences at Stanford University and author of “CRISPR People: The Science and Ethics of Editing Humans.” Antonio Regalado – Senior Editor for Biomedicine, MIT Technology Review. originally posted April 17, 2023 Big Picture Science is part of the Airwave Media podcast network. Please contact advertising@airwavemedia.com to inquire about advertising on Big Picture Science. You can get early access to ad-free versions of every episode by joining us on Patreon. Thanks for your support! Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's episode of Medicine: The Truth, hosts Jeremy Corr and Dr. Robert Pearl probe the facts beneath healthcare's biggest headlines. Today's show opens with a scientific breakthrough that could change the future of inherited disease: a new gene-editing technique that may allow researchers to correct DNA errors in human embryos with far greater precision than earlier CRISPR approaches. Dr. Pearl explains that the advance, developed by researchers at Columbia University, uses a method called base editing. Unlike traditional CRISPR, which cuts out and replaces sections of DNA, base editing can alter individual nucleotides (the “letters” that make up genetic code). The difference, Pearl says, is comparable to moving from rewriting entire pages of text to correcting a single wrong letter inside a single word. The promise is extraordinary. For families affected by one of the thousands of rare genetic diseases caused by single DNA errors, this technology could one day make it possible to prevent devastating inherited conditions before birth. Children who otherwise might face blindness, severe disability or premature death could instead be born free of the genetic defect. But the ethical concerns are equally profound. The same technology that could prevent horrific disease could also be used to modify embryos for non-medical traits. Pearl warns that this possibility raises fears about “designer babies,” eugenics, private-sector incentives and the lack of federally funded oversight for embryo research in the United States. Here are the other major storylines from episode 108: A large study of 9 million patients found that four risk factors (high blood pressure, diabetes, high cholesterol and smoking) are associated with nearly all heart attacks and strokes. The FDA approved a new sunscreen ingredient already used in Europe for decades, highlighting both the promise of better melanoma prevention and the slow pace of U.S. sunscreen regulation. Employers are preparing for further increases in healthcare premiums, deductibles and copayments, with many companies limiting or eliminating GLP-1 coverage for obesity. Preliminary data show U.S. infant mortality has reached an all-time low, but progress remains slow. Medicaid work requirements could cause millions of eligible people to lose coverage because of paperwork errors, shifting costs to emergency rooms, hospitals and state budgets. New rules under the No Surprises Act aim to speed dispute resolution between insurers and providers, but Pearl warns that payment disputes will continue as long as healthcare costs rise faster than people's ability to pay. Pearl outlines three requirements for real healthcare transformation: keeping people healthy by controlling chronic disease, moving more care into the home with generative AI support and shifting payment from fee-for-service to capitation. The episode closes with two examples of AI already helping clinicians see what they might otherwise miss. Tune in to hear the full discussion and subscribe to Medicine: The Truth for more fact-based analysis of the medical, scientific and policy stories shaping American healthcare. * * * Dr. Robert Pearl is the author of “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine” about the impact of AI on the future of medicine. Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn. The post MTT #108: Designer babies, chronic disease & AI-powered care appeared first on Fixing Healthcare.

In this episode, Ray Cochrane unpacks how two colliding black holes revealed a whirlpool in spacetime, a direct detection of frame dragging hidden in the cleanest gravitational-wave signal ever recorded. Additional stories cover the James Webb Space Telescope, counting 16.5 million stars in the Cigar Galaxy, SpaceX rolling out Starship V3, deadly back-to-back earthquakes in Venezuela, GitHub fighting a California law that could break open source, and Meta engineering a battery narrow enough to live in a pair of glasses. – Want to start a podcast? It’s easy to get started! Sign-up at Blubrry – Thinking of buying a Starlink? Use my link to support the show. Subscribe to the Newsletter. Email Ray if you want to get in touch! Like and Follow Geek News Central’s Facebook Page. Support my Show Sponsor: Best Godaddy Promo Codes Get 1Password Full Summary Cochrane opens with a personal update before the night’s lead story. He recently graduated with a Bachelor of Science in Computer Science from Portland State University, celebrated with family in town, and launched a new site at rayc.world. That site links to a final-project study he built on collaborative filtering using podcasting data, hosted at cohort.rayc.world and drawn from OP3 analytics. He also plans to return to the show’s classic twice-weekly cadence on Mondays and Thursdays. From there, he goes deep on a new black hole discovery, then pivots through space, earth science, climate, biotech, open source, cloud infrastructure, and consumer hardware. Colliding Black Holes Reveal a Whirlpool in Spacetime Two black holes spiraled together, merged, and sent a gravitational wave rippling across the universe. Researcher Neil Lu and colleagues at the Australian National University found the fingerprint of frame dragging buried in GW250114, the cleanest signal LIGO has ever recorded. Frame dragging means a spinning black hole drags spacetime around with it, like a spoon turning in honey, except the honey is reality itself. Remarkably, the wave changed the distance between your nose and your ear as it passed, by far less than the width of a single atom. Sponsor: GoDaddy Economy hosting is $6.99/month, WordPress hosting is $12.99/month, and domains are $11.99. Website builder trial available. Use codes at geeknewscentral.com/godaddy to support the show. Webb Counts the Stars in the Cigar Galaxy NASA released a striking new James Webb Space Telescope view of Messier 82, the edge-on galaxy nicknamed the Cigar Galaxy. Because Webb sees in infrared, it peers straight through the dust that normally hides the galaxy’s interior. Combined with archival Hubble data, the image resolves roughly 16.5 million individual stars. M82 is a starburst galaxy, meaning it forms stars at a furious rate, a frenzy likely triggered when it merged with a neighbor. SpaceX Rolls Out Starship V3 SpaceX officially introduced Starship V3, the third generation of the largest rocket ever built. The vehicle now flies on the Raptor 3 engine, pushing liftoff thrust to around 20 million pounds and making it the most powerful rocket ever flown. More importantly, V3 is designed to carry over 100 metric tons to low Earth orbit while staying fully reusable, roughly triple the previous version. SpaceX also added in-orbit refueling hardware, the capability that finally makes operational Moon and Mars missions realistic. The Asteroid Barrage That Kept Earth From Forming Continents A team led by Curtin University and the Queensland University of Technology argues that relentless asteroid impacts shaped the very young Earth. During the Hadean, more than four billion years ago, the planet was struck far more often than it is today. Each impact dumped heat deep into the interior, repeatedly melting and reworking the crust. Consequently, stable continents formed much later than calmer models assumed, painting a picture of a hotter, weaker, more chaotic early Earth. Back-to-Back Earthquakes Devastate Northern Venezuela Northern Venezuela was struck by two major earthquakes on June 24, a magnitude 7.2 foreshock followed by a magnitude 7.5 mainshock. Both hit only about six miles underground, so the shallow shaking delivered its full force at the surface. Tragically, at least 164 people died, and the region sits along the tangled boundary where the Caribbean and South American plates grind past each other. These were the largest quakes to hit the area since a magnitude 7.7 event near Caracas in 1900. The ‘Guerrilla Solar’ Era Has Arrived A quiet energy shift, nicknamed “guerrilla solar,” is spreading across Europe. These small plug-in panels deliver power to a home’s wiring via a standard wall outlet, with no electrician or permit required. Germany now counts roughly a million of these systems. However, the U.S. payoff remains modest, with savings estimates of around $15 per month against a $500 to $1,500 setup cost. Why a Broken-Up Forest Stores Less Carbon Researchers quantified what foresters long suspected: an intact forest stores far more carbon than the same acreage split into fragments. A hectare inside a large, continuous forest proved about 38 percent more productive than an isolated one. The culprit is edge effects, the extra wind, heat, and direct sun that stress trees at a forest’s boundary. Because a large forest maintains a large protected core while fragments are nearly all edge, planting trees together matters for carbon storage. Edited Human Embryos Reveal a Surprise Researchers used base editing, a precise cousin of CRISPR that rewrites a single DNA letter without cutting the strand, in human embryos. They discovered that a protein called NANOG plays a role in early human development that it does not play in mice. In humans, switching it off still let cells form that seed the placenta and yolk sac. The finding argues that understanding human development requires studying human embryos directly, which reignites a thorny ethical debate. GitHub Fights a California Law That Could Break Open Source GitHub joined Black Forest Labs, Hugging Face, and Mozilla to push for fixes to California’s AI Transparency Act. As written, the bill could force revocation of an open-source license when a downstream user fails to meet certain obligations, which clashes with the permanent, irrevocable promise of open source. Cochrane pointed to curl and its longtime maintainer, Daniel Stenberg, warning that the rule could destabilize the supply chain on which the whole tech world runs. Instead, the coalition points to the EU’s AI Act transparency code as a saner model. Rust Opens Its Maintainers Fund The Rust Foundation launched a Maintainers Fund to pay the people who keep the language’s ecosystem healthy. Backed by RFC 3931, it establishes a funding team and a new Maintainer-in-Residence program for the often thankless work on the compiler, standard library, Cargo, and Clippy. Individuals can donate through GitHub Sponsors, while companies can sponsor there or contact the foundation directly. Cochrane urged any business that depends on open source to invest in the projects it actually uses. AWS Gives Lambda Its Own Isolated Sandboxes AWS introduced MicroVMs inside Lambda, its serverless platform. Each session runs in a dedicated micro virtual machine with no shared kernel and up to eight hours of total runtime. The feature exists for the AI era, in which applications increasingly run code written by an AI agent rather than by the developer. Use cases include AI coding assistants, data analytics platforms, vulnerability scanners, and game servers running user-supplied scripts. Meta Engineers a Battery Narrow Enough for Glasses Meta built custom steel-can battery cells as narrow as seven millimeters to fit the temple arms of smart glasses like the Ray-Ban Meta and Oakley Meta Vanguards. These cells power cameras, speakers, and AI features in a space most engineers would call impossible. To prevent brownouts, Meta swapped wound electrodes for precisely die-cut stacked layers that lower electrical resistance. Now the company is spreading the technology across multiple vendors and eyeing other wearables. Polestar Gets Locked Out of the US Market Starting in 2027, Polestar will not be able to sell its new models in the United States. A federal Connected Vehicle Rule bars cars containing certain Chinese or Russian software or hardware on national security grounds. The painful irony is that Polestar moved production of the Polestar 3 to South Carolina specifically to dodge tariffs on Chinese-built EVs. Because the rule targets the technology’s origin rather than its assembly location, the company is shut out anyway. Retroid’s Pocket Nova Packs Serious Power for $229 Retroid returned with a new retro handheld, the Pocket Nova, starting at $229 with a step-up model around $269. It features a 4.5-inch AMOLED screen in a 4:3 aspect ratio, a shape well suited to classic games. On paper, it should handle GameCube- and PlayStation 2-era titles, though that remains an early expectation rather than a benchmarked promise. Retroid has earned a strong reputation for high-quality, genuinely portable consoles. Cochrane signs off with the usual ecosystem mentions: GNC Insider at geeknewscentral.com/insider, the show newsletter, email at geeknews@gmail.com, and modern podcast app recommendations at podcastapps.com. The post Colliding Black Holes Reveal a Whirlpool in Spacetime #1866 appeared first on Geek News Central.

About this episode:   A group of students from suburban Atlanta has developed a new method for detecting Lyme disease using the gene-editing tool CRISPR. In this episode: why there's such a desperate need for a new diagnostic, how the students' model works, and why it's so promising for the treatment of Lyme and other diseases.  Guest:  Nicole Baumgarth, PhD, DVM, is Bloomberg Distinguished Professor in Molecular Microbiology and Immunology and the director of the Lyme and Tickborne Disease Research and Education Institute at the Johns Hopkins Bloomberg School of Public Health.  Sankalp Yeleti is a recent graduate of Lambert High School and a rising freshman at New York University, where he plans to study biomolecular science.  Host:  Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health.  Show links and related content:  Teens may have come up with a new way to detect, treat Lyme disease using CRISPR gene editing—CBS News  Lancet—Lambert iGEM 2025 Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Welcome, Massimo Banzi of SuperModerno and co-founder of Arduino Introduction and SuperModerno: Massimo introduces himself as a “friendly nerd” and discusses his new project, SuperModerno The project aims to explain the “behind the scenes” of technology to prevent people from becoming “slaves to the platform” The History of Technology: Massimo expresses his passion for technology’s history, emphasizing non-American innovators to show Europeans they can also lead in technology, citing the UK-based origins of the Arm processor The Legacy of Olivetti: He highlights Olivetti (founded in 1908), which moved from typewriters to creating the Programma 101, the first desktop computer used by NASA to compute orbits for the Apollo program Design as a Differentiator: Olivetti was the first tech company to apply design to everything (products, posters, and architecture) This inspired Massimo's concept of the “invisible touch”, the idea that consistent, intentional design creates a unique connection with users and gives a company a competitive edge The Interaction Design Institute Ivrea (IDII): Massimo’s path led him to IDII, located in the former Olivetti research building, where he transitioned from a two-week sabbatical to a four-year stay Learning by Making: To help students with no electronics background, Massimo drew on how he learned as a seven-year-old (“learning by making”) to remove the friction of interacting with technology The Founding Team: He met Tom Igoe (ITP) and David Cuartielles, and they realized students were afraid to be creative because they feared “blowing up” expensive tools like the Basic Stamp The “Pizza and a Beer” Price Point: Massimo aimed for a hardware cost of 20 Euros, roughly what a student would spend on a pizza and a beer, to encourage experimentation Building the Platform: Along with David Mellis, the team adapted Processing (a language for artists) by “surgically” replacing Java with C++ to create the Arduino IDE Ivrea Manufacturing: Leveraging the industrial base of Ivrea and Torino (the “Detroit of Italy”), Massimo was able to find local PCB manufacturers and assemblers just a short drive away From Hacking to AVR: Massimo's early work involved hacking satellite TV PIC chips for soccer fans, but mentor Bill Verplank encouraged him to use AVR microcontrollers because they could be programmed simply in C Enabling Creators: Massimo shares stories of how Arduino enabled others, such as Josef Prusa, who started with Arduino as a teenager before building his global open-source 3D printer company The Innovation of Simplicity: Massimo argues that Arduino’s true innovation is the user experience This is measured by the “Time to First Blink”, the goal for a user to go from downloading software to blinking an LED in five minutes Standardization and “The Core”: Arduino became an ad-hoc standard by providing a compatibility layer across different microcontrollers Massimo believes in having a “small slice of a really large pie” by allowing other architectures to work within the ecosystem Hardware Architecture and the “Lasagna”: Inspired by the PC104 format, the board uses a layered approach where modules stack like a lasagna The “Shield of a King”: The name Arduino comes from King Arduino of Ivrea; David Cuartielles suggested that since the board was named after a king, the add-on modules should be called “Shields” Hardware Design Choices: The board fits a credit card size (to stay within the free version of Eagle software) and is blue because that color was thought to be less tiring for workers’ eyes Happy Accidents: The unique shape was chosen to be “ourselves instead of everyone else” During the design process, Massimo inadvertently moved a connector by half a step, creating an offset header that they kept for consistency after the first few thousand were made The Discovery of Auto-Reset: During a workshop in Germany, Massimo solved the frustration of manual resets by soldering a capacitor to the DTR pin, allowing the software to trigger the reset automatically The US Market and Legal Battles: Tom Igoe's adoption of Arduino at NYU helped the US become the project’s single biggest market This growth led to a difficult legal battle for control of the brand against a former partner Support from Arm: Massimo credits Arm Ltd (and CEO Simon Segars) for providing the strategic support that allowed the founders to regain control of the company. Massimo believes this is the first time he has talked about the role of Arm in the difficult legal process. Industrial and AI Expansion: Partnerships with Intel and Microsoft (Windows 10 IoT) led to early forays into TinyML (AI on small boards) back in 2017 The Qualcomm Acquisition: In October 2025, Qualcomm acquired Arduino, which Massimo sees as essential for bringing “advanced silicon” into the family to handle the increasing complexity of technology The “Arduino Formula” and Layering: Massimo views Arduino as a formula for simplification that can be applied to anything, including complex Linux machines like the Uno Q This is achieved by building in layers, where beginners use high-level abstractions and experts can “strip away” layers to reach the bare metal The Future Vision: Massimo looks forward to the “Arduino Formula” being applied to new fields, stating he is waiting for someone to develop an “Arduino for biology” using CRISPR and DNA technology

Thomas is joined by Dr. Eric Jaffe, biologist, dinosaur enthusiast, and high school biology teacher, for a conversation that starts with a deceptively simple question: what are biological definitions actually doing? It turns out that biology is far more like history than math, and that difference has enormous consequences for anyone trying to weaponize phrases like "the biological definition of sex." Dr. Jaffe walks through why definitions in inductive sciences are descriptive, not prescriptive, and what that means for species, chromosomes, fungi, LeBron James, and trans people. "Exceptions aren't the exceptions in biology. They are built into what we call biological systems." Plus: Patreon Q&A questions on alien DNA, how new chromosomes evolve, the 97% chimp figure, CRISPR vs. what came before, and Trump's research budget cuts. Cells at Work (anime recommended by Dr. Jaffe) Project Hail Mary (film referenced) Are you an expert in something and want to be on the show? Apply here! Please support the show on Patreon! You get ad-free episodes, early episodes, and other bonus content! https://www.patreon.com/seriouspod